Synspira Therapy Could Revolutionize the Battle Against Cystic Fibrosis

Researchers stressed that glycopolymer proved most effective in comparison to all other types of multidrug-resistant MRSA bacteria and respiratory bacteria that they had tested. It re-sensitized the bacteria to the antibiotics, making them more vulnerable. “The results published in PLOS ONE demonstrate that our inhaled glycopolymer drug candidate, PAAG, has the potential to significantly enhance the activity of antibiotics that are used for the treatment of lung infections caused by Burkholderia cepacia complex, a relatively uncommon but often fatal infection in cystic fibrosis. By breaking down the outer membrane of the bacteria, PAAG makes bacteria more susceptible to antibiotics, even in species that were previously resistant to antibiotic therapy. We believe that our formulated drug SNSP113 using PAAG has the potential to address a key unmet need in these types of infections and to be a new approach to the growing problem of antibiotic resistance in pulmonary indications,” said Baker.